昭衍新藥(603127.SH):H股的發行價區間初步確定為133-151港元
格隆匯 2 月 17日丨昭衍新藥(603127.SH)公佈,根據發行上市的時間安排,公司於2021年2月16日在香港刊登並派發了H股招股説明書。該H股招股説明書可於香港聯交所網站進行查詢,香港聯交所網址為:
中文:https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0216/2021021600010_c.pdf
英文:https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0216/2021021600009.pdf
公司本次全球發售H股總數為4332.48萬股(視乎超額配股權行使與否而定),其中,初步安排香港公開發售389.93萬股(可予調整),約佔全球發售總數的9%;國際發售3942.55萬股(可予調整及視乎超額配股權行使與否而定),約佔全球發售總數的91%。
自香港公開發售截止日後起30日內(即2021年3月21日前),聯席全球協調人(代表國際承銷商)還可以通過行使超額配售權,要求公司額外增發不超過649.87萬股H股。
公司此次H股發行的價格區間初步確定為133港元至151港元。公司H股香港公開發售已於2021年2月16日開始,預計於2021年2月19日結束。預計定價日為2021年2月19日,並預計於2021年2月25日公佈發行價格。
公司此次發行的H股預計於2021年2月26日在香港聯交所掛牌並開始上市交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.